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Abstract
Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, 
most recently has shown promise for treating cocaine dependence. Although DSF’s mechanism of 
action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase 
(ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a 
pro-drug, forming a number of metabolites each with discrete pharmacological actions. One 
metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione 
(carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present 
studies, we employed microdialysis techniques to investigate the effect of carb administration on 
dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial 
prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect 
of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in 
male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased 
GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc 
and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC 
carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 
min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for 
approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb 
administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) 
also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that 
observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-
benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be 
detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. 
Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was 
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administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect 
on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb 
showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as 
the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of 
carb and the area under the curve (AUC) were similar after both routes of administration. It is 
concluded that carb must be formed from DSF before any changes in DA, GABA, and GLu in the 
NAc and mPFC are observed. DSF and carb, when administered to rats, co-release DA, GABA, 
and GLu. Carb, once formed can cross the blood brain barrier and enter the brain. Although 
inhibition of liver ALDH2 is the accepted mechanism for DSF’s action in treating AUDs, the 
concurrent changes in DA, GABA, and GLu in the NAc and mPFC after DSF administration 
suggest that changes in these neurotransmitters as a potential mechanism of action not only for 
AUDs, but also for cocaine dependence cannot be excluded.
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1. Introduction
Disulfiram (DSF), accidentally discovered approximately 65 years ago, has been used since 
then as a deterrent for alcohol use disorders (AUDs) (Hald and Jacobson, 1948). Clinical 
studies also have shown DSF to be a useful drug candidate for the treatment of cocaine use 
(Carroll et al., 1998, 2000; George et al., 2000; Petrakis et al., 2000; Carroll et al., 2004). 
Recently, DSF also has shown promise in the treatment of non-substance abuse disorders 
such as pathological gambling (Reuter et al., 2005). At this time other than for AUDs, there 
are no pharmacotherapies currently approved by any regulatory agency for the treatment of 
cocaine use or pathological gambling disorders. Although DSF’s mechanism of action in 
treating AUDs is established as being due to its inhibition of liver mitochondrial aldehyde 
dehydrogenase (ALDH2), the mechanism of action of DSF in treating cocaine dependence 
or pathological gambling is unknown, but suggests a central mechanism. Seminal studies 
(Yourick and Faiman, 1989, 1991) showed DSF to be a pro-drug that requires bioactivation, 
and a number of metabolites are formed each with discrete pharmacological properties. The 
chemical pathways, the metabolites formed, including the metabolite S-methyl N, N-
diethylthiolcarbamate sulfoxide (DETC-MeSO) which is responsible for ALDH2 inhibition 
which is responsible for the anti-alcohol effect (Hart and Faiman, 1992), and the respective 
cytochrome P450 and other enzymes identified in DSF’s bioactivation have been described 
previously in a comprehensive series of studies (Fig. 1) (Madan et al., 1993; Hart and 
Faiman, 1993; Madan and Faiman, 1994a; Madan and Faiman, 1994b, 1995; Madan et al., 
1994; Madan and Faiman, 1995; Madan et al., 1995, 1998).
The finding that DSF was effective independent of concurrent alcohol use (Carroll et al., 
2004), and coupled with previous studies that carb does not inhibit ALDH2 (Jin et al., 1994; 
Nagendra et al., 1997), suggested DSF’s mechanism of action for the treatment of cocaine 
dependence must be due to a metabolite further downstream from DETC-MeSO (Fig. 1). 
Since the concentration of reduced glutathione (GSH) in vivo is high (1–6 mM) (Potter and 
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Tran, 1993), the DSF metabolites DETC-MeSO and S-methyl N, N-diethylthiolcarbamate 
sulfone (DETC-MeSO2) (Jin et al., 1994; Nagendra et al., 1997) rapidly carbamoylate the 
sulfhydryl of glutathione to S-(N, N-diethylcarbamoyl) glutathione, the metabolite of 
interest and is referred to as carbamathione (carb) (Schloss, 2007) (Fig. 1).
In earlier studies, we showed that the i v administration of carb to mice irreversibly blocks 
glutamate binding to mouse brain synaptic membranes (Nagendra et al., 1997), and 
speculated that carb may affect both the N-methyl-D-aspartate (NMDA) and non-NMDA 
glutamate receptor subtypes. NMDA receptor antagonists are known to increase brain DA 
(Cano-Cebrian et al., 2003). Non-competitive NMDA receptor antagonists (Thomson et al., 
1985) also increase the release of glutamate (GLu) from the PFC (Moghaddam et al., 1997; 
Del Arco and Mora, 2002; Lorrain et al., 2003) and NAc (Razoux et al., 2007), and DA from 
the PFC (Moghaddam et al., 1997; Lorrain et al., 2003). The glutamatergic system also 
modulates DA in the NAc (Imperato et al., 1990a, 1990b; Youngren et al., 1993; Taber et 
al., 1996; Sesack et al., 2003). Pharmacological modulation of the GABAergic system in 
cocaine-treated rats affects extracellular DA in the NAc. In addition, several studies reported 
that GABA-transaminase inhibition increase GABA and DA (Gerasimov et al., 2001; 
Dewey et al., 1998; Morgan and Dewey, 1998; Pan et al., 2012). Both DA and GLu also 
have been implicated in cocaine dependence (Kalivas, 2007). Thus, DA, GABA, and GLu 
appear inter-related in the addictive process for cocaine, and possibly other drugs of abuse, 
as those studies as well as others (Tzschentke and Schmidt, 2003; Spanagel and Kiefer, 
2008; Uys and LaLumiere, 2008) have shown.
Cocaine dependence, as well as other substance abuse disorders is considered to be a brain 
disease (Leshner and Koob, 1999). Thus, efforts have been made to identify psychoactive 
agents that affect the dopaminergic, GABAergic, and glutamatergic pathways, and evaluate 
their potential in treating cocaine dependence (Preti, 2007; Gass and Olive, 2008; Karila et 
al., 2008; Shorter and Kosten, 2011; Somaini et al., 2011). Unfortunately, the clinical 
effectiveness of these agents is inconsistent (Vocci and Ling, 2005; Pierce and Kumaresan, 
2006; Preti, 2007; Kampman, 2010; Shorter and Kosten, 2011). Given that DSF’s efficacy in 
treating cocaine dependence appears independent of ALDH2 inhibition (Carroll et al., 2004), 
that carb seems to have an effect on GLu binding (Nagendra et al., 1997), and the inter-
dependent relationship between DA, GABA, and GLu (Sesack et al., 2003; Lapish et al., 
2006; Del Arco and Mora, 2008), we hypothesized that the DSF metabolite carb may be 
responsible for the increase in brain DA after DSF administration, and also possible changes 
in GABA and GLu. To test this hypothesis we carried out microdialysis studies to determine 
carb’s effect on these neurotransmitters in the NAc and mPFC, two brain regions central to 
the addictive process (McFarland and Kalivas, 2001). DA, GABA and GLu were determined 
concurrently since all three neurotransmitters have been implicated in cocaine dependence 
(Kalivas, 2007).
2. Methods
2.1. Chemicals, reagents, and drugs
All chemicals, reagents, and solutions used for the analysis of DA, GABA, and GLu, have 
been described previously (Kaul et al., 2010, 2011). Carb was synthesized using the method 
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of Jin et al. (1994) with modification (Schloss, 2007). DSF and N-benzylimidazole (NBI) 
were purchased from Sigma–Aldrich, St. Louis, MO, USA).
2.2. Analytical procedures
Analysis of NAc and mPFC DA, GABA, GLu and carb in microdialysis samples in the carb 
dose–response studies (Figs. 2–4) were carried out utilizing a previously developed method 
employing micellar electrokinetic chromatography with laser-induced fluorescence (MEKC-
LIF) (Kaul et al., 2011) which measured DA, GABA, and GLu simultaneously in both the 
NAc and mPFC (Kaul et al., 2011). The detection and quantification of carb in the 
microdialysis samples from the plasma was determined concomitantly with these 
neurotransmitters using recently developed LC MS/MS techniques (Kaul et al., 2010).
2.3. Animals, surgeries, and microdialysis studies
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 300 g 
to 400 g were used. Rats were housed in a temperature and humidity controlled animal 
facility maintained on a 12 h light/dark cycle with access to food and water ad libitum. 
Animals were brought into the laboratory from the animal facility, kept individually in their 
cage, and acclimated for 24 h before studies were initiated. Experiments were conducted 
during the light phase. Prior to surgery, the rats were initially anesthetized by isofluorane 
inhalation, followed by a subcutaneous injection of a mixture of ketamine (67.5 mg/kg), 
xylazine (3.4 mg/kg) and acepromazine (0.67 mg/kg).
Rats were implanted with an i v catheter for the carb or an intraperitoneal (i p) catheter for 
the DSF drug-dosing studies followed by the vascular and brain microdialysis probes. For i 
v drug-dosing, a PE-10 cannula (Fisher Scientific, Pittsburgh, PA) was implanted into the 
external femoral vein, with the cannula exiting the skin of the rat at the back of the neck 
between the shoulders (Kaul et al., 2011). For the DSF i p studies, a recently developed 
route of administration was employed which minimized animal handling since 
neurotransmitter concentrations can change as a result of stress associated with animal 
handling. This technique avoided this possibility. A 5–10 cm of PE-50 cannula (Fisher 
Scientific, Pittsburgh, PA) was inserted into the abdominal cavity so that the end of the 
cannula lay between the small intestine and the ventral cavity wall. The cannula was held in 
place by suturing it to the edge of the opening in the muscle wall. The muscle incision was 
sutured and the free end of the cannula was externalized through an incision at the back of 
the neck between the shoulders. This i p technique allowed the drugs to be administered to 
the rats without the need to handle each animal multiple times for drug-dosing.
The dialysis brain probes for determining the neurotransmitters in the shell of the NAc and 
in the mPFC were implanted as follows. Holes 1 mm in diameter were drilled through the 
skull at the insertion sites and intra-cerebral guide cannulas were lowered into the specified 
regions using a micromanipulator attached to the stereotaxic apparatus. The guide cannulas 
were positioned 2 mm above the specified regions and then affixed to the skull with dental 
cement. The dummy probe in the guide cannula was replaced with microdialysis probes 
(CMA 12 Elite) with 2 mm membranes purchased from CMA Microdialysis (North 
Chelmsford, MA). The coordinates of the insertion sites relative to the bregma line were 
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+1.5 mm anterior, +0.9 mm lateral and −6.2 mm ventral for the NAc shell site and +3.7 mm 
anterior, +0.7 mm lateral and −1.0 mm ventral for the mPFC (Paxinos and Watson, 1986). 
After the surgical procedures, the rats were administered 0.5–3 ml/kg of saline 
subcutaneously to prevent dehydration. A heating pad was placed under the rats to provide 
warmth during recovery from anesthesia. Plasma carb samples were obtained from a 
microdialysis probe implanted into the jugular vein utilizing vascular probes that were 
fabricated in-house. After surgical implantation, the brain and vascular probes were perfused 
with aCSF and Ringer’s solution respectively at a rate of 2 µL/min. The perfusion and 
collection of three minute samples in the microdialysis dose–response studies after carb 
administration or five minute collection times after DSF was initiated 24 h after surgery. 
This same post-surgery time period before initiation of the studies has been used 
successfully by others (Devoto et al., 2012).
2.4. Microdialysis probe calibration
Microdialysis samples were collected using a CMA 100 micro infusion pump and a 
HoneyComb fraction collector (Bioanalytical Systems Inc., West Lafayette, IN). The 
characteristics of the implanted microdialysis probes were evaluated at the end of each 
experiment. The relative recovery of carb through the microdialysis probes was estimated by 
delivery experiments (Song and Lunte, 1999) by perfusing 1 µmol/L carb through the 
microdialysis probes in vivo at 2 µL/min and determining the percentage that perfused 
through the membrane. The in vivo extraction efficiency (mean ± SEM) for carb was 
determined to be 25.8 ± 4.1% for the brain probes and 57.5 ± 10.4% for the plasma vascular 
probes. The concentration of carb determined in the microdialysis samples was corrected for 
the extraction efficiency of the probe used. The in vitro extraction efficiency (mean ± SEM) 
for DA, GABA, and GLu was estimated to be 14.1 ± 1.9%,17.2 ± 1.8%, and 13.5 ± 1.4% 
respectively. The concentrations of DA, GABA, and GLu were expressed as percent (mean 
± SEM) of baseline concentrations in order to monitor changes from basal levels after either 
carb or DSF administration.
2.5. Drug dosing
Carb (20, 50, and 200 mg/kg i v) was prepared in sodium bicarbonate solution (Kaul et al., 
2010). DSF was prepared as a suspension in saline solution and then sonicated, and 
administered at a dose of 200 mg/kg i p. NBI was prepared in saline with a few drops of 0.1 
mol/L HCl added and the solution sonicated. The dose of NBI administered was 20 mg/kg i 
p (Hart and Faiman, 1993). In the studies with carb, microdialysis sampling was carried out 
every three minutes. In these dose–response studies, a sample size of five rats per dose of 
carb was used. After all probes were in place in each rat, perfusion with aCSF was initiated 
60 min before the i v administration of carb. At this time neurotransmitter concentrations 
were stable (Figs. 2 and 3). Carb was then administered i v for each dose of carb and 
microdialysate samples collected every three minutes for two hours. This procedure was 
repeated for a total of five rats for each dose of carb studied which constituted the sample 
size. For the DSF experiments (Figs. 6 and 7), this dosing procedure was repeated except 
that in the DSF or DSF plus NBI studies the drugs were given i p using the newly developed 
technique, and microdialysate sampling carried out every five minutes. This procedure was 
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repeated for a total of three rats for each dose of DSF or DSF plus NBI which constituted the 
sample size.
2.6. Histology
At the completion of each experiment, the rats were killed by placing the animal in an 
isofluorane chamber for 30 min. Rat brains were harvested for histological confirmation of 
brain probe position. The rat brains were fixed in buffered formalin (10%). The tissues were 
embedded in paraffin wax and the sections cut at 5 µm and stained with hematoxylin-eosin. 
Only probes with at least 85% of the active dialysis membrane in the NAc shell or mPFC 
were included in the study.
3. Animal use
All animal experiments were conducted during the light phase and in accordance with 
guidelines established by the Institutional Animal Care and Use Committee at the University 
of Kansas and in accordance with NIH approved guidelines and met AAALAC standards.
4. Data and statistical analysis
In Figs. 2–8, data are given as mean ± SEM. Values for the first five consecutive samples 
were averaged to calculate basal neurotransmitter levels. In the carb and DSF studies, the 
start of drug administration (time point zero) was corrected for the lag time of the 
microdialysis system. For the carb dose–response studies, statistical and post-hoc analysis 
were performed with two-way repeated measures analysis of variance (RM ANOVA) to 
compare neurotransmitter levels between treatment doses (between-group factor) and 
treatment over time (repeated measures factor). For the DSF plus NBI inhibition studies, a 
one-way ANOVA was performed separately for each neurotransmitter (DA, GABA, GLu) 
(Table 3) and phase (I, II, III) (Fig. 7) to determine if drug treatments were significantly 
different from each other. Each phase refers to the time period when measurements were 
obtained. Phase I was 30 min before any drug treatment, Phase II was 30 min after the first 
NBI treatment, and Phase III was the 35 min period within the region of the maximal DA 
response. When phase-related one-way ANOVAs were significant, post-hoc tests were 
carried out (Bonferroni) to determine if the DSF treatment was significantly different from 
the other two treatments. The α level for statistical significance was set at p < 0.05 for all 
comparisons. When assumptions for homoscedasticity were not supported, ANOVAs were 
based on log10 transformations of the data.
5. Results
5.1. Carbamathione and NAc dopamine, GABA, and glutamate
Carb (20 mg/kg, 50 mg/kg, and 200 mg/kg i v) increased DA 96%, 232%, and 616%, (p < 
0.05) respectively in the NAc shell (Fig. 2), with the maximal increase occurring 
approximately 15 min after drug administration. Extracellular GABA decreased 23%, 42%, 
and 77%, respectively (p < 0.05) at these three doses, with the maximal decrease occurring 
approximately 45 min after carb administration. GLu in the NAc exhibited a biphasic effect. 
Initially, GLu increased 29%, 37% and 101% (p < 0.05) after each dose of carb, remained 
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elevated for approximately 39 min, after which GLu then decreased 26%, 39%, and 84%, 
respectively (p < 0.05) below basal levels.
5.2. Carbamathione and mPFC dopamine, GABA, and glutamate
In the mPFC (Fig. 3), after i v carb (20 mg/kg 50 mg/kg and 200 mg/kg) administration, 
extracellular DA increased 66%, 159%, and 395% respectively (p < 0.05), although the 
increase in DA was less than that seen in the NAc. Carb also decreased extracellular GABA 
29%, 47%, and 82% at these three doses (p < 0.05). As observed in the NAc, carb also 
produced a biphasic effect on extracellular GLu in the mPFC. Initially, extracellular GLu in 
the mPFC increased 35%, 70%, and 140% (p < 0.05) respectively at the three doses, and 
remained elevated for approximately 30 min, after which GLu then decreased of 29%, 47%, 
and 79% below basal levels for approximately one hour after drug administration before 
returning to base-line values. These changes in GABA and GLu were similar to those found 
in the NAc. As observed in the NAc, the greater the dose of carb administered, the greater 
the change in DA, GABA, and GLu in the mPFC.
Of interest was that the peak increase in DA in the NAc at all three doses occurred 
approximately 15 min after carb dosing whereas in the mPFC (Fig. 3) the peak effect 
occurred approximately 50 min after drug administration. Furthermore the peak DA 
concentration reached in the NAc was greater than that in the mPFC. The time for the 
maximal decrease in GABA and times for the changes in GLu were similar to those in the 
NAc.
5.3. Post-hoc analysis of carbamathione on NAc and mPFC dopamine, GABA, and 
glutamate
Post-hoc analysis (Table 1) of the effect of these doses (treatment-dose) on DA in the NAc 
showed that the effect of 200 mg/kg of carb was significantly different than from a dose of 
50 mg/kg and 20 mg/kg but the 50 mg/kg dose was not statistically different from the 20 
mg/kg dose. This was the same for GLu. For GABA, post-hoc analysis found statistically 
significant differences between all three doses of carb. In the mPFC, post-hoc analysis 
showed a statistically significant increase in DA and a decrease in GABA at all three doses. 
For GLu, only the 50 mg/kg versus the 20 mg/kg dose showed no statistically significant 
difference (Table 1). The lack of statistical significance between the 50 mg/kg and 20 mg/kg 
dose after carb administration for GLu in the NAc and mPFC appears to be due to the 
greater variability in neurotransmitter concentration and limited sample size.
5.4. Concentration–time profile of carbamathione in NAc, mPFC, and plasma
A comparison of the concentration–time profile between carb in the NAc, mPFC, and in the 
plasma after each i v dose of drug is given in Fig. 4A and B respectively. The peak 
concentration of carb in the NAc and mPFC occurred after 5 min, and in the plasma 
approximately 3 min after carb administration at the respective doses and then decreased 
rapidly. The rapid loss of carb in the NAc and mPFC (Fig. 4A) and in plasma (Fig. 4B) was 
in contrast to the changes in extracellular DA, GABA and GLu observed in the NAc (Fig. 2) 
and mPFC (Fig. 3). In those brain regions the increase in DA, decrease in GABA, and the 
biphasic effect that occurred with GLu were maintained for at least two hours. This suggests 
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that there is no relationship between the concentration of carb in the NAc, mPFC or in 
plasma and the effect of carb on DA, GABA, and GLu in these brain regions.
5.5. Pharmacokinetic parameters
The various pharmacokinetic parameters for carb in the NAc, mPFC, and in plasma are 
given in Table 2. There was a direct relationship between the i v dose of carb administered 
and the carb Cmax and AUC in both the NAc and mPFC, and in the plasma. The carb tmax, 
t1/2, and Kelim were similar in both the NAc and mPFC and in plasma irrespective of the 
dose of carb administered, suggesting a diffusion process and a first-order mechanism.
5.6. Disulfiram and NAc dopamine, GABA, and glutamate
After DSF (200 mg/kg i p) administration, carb was found in the NAc (Fig. 5A). The 
concentration of carb in the NAc was less than the concentration of carb found in the NAc 
after i v carb (Fig. 5B). Similarly, carb in plasma after DSF (Fig. 5A) was less than the 
concentration of carb in plasma after carb administration (Fig. 5B). The time for carb to 
reach the maximal concentration (tmax) after DSF was greater (90 min) than after carb (5 
min) dosing. These differences would be expected since carb was given i v whereas DSF 
was administered i p which requires DSF to be absorbed and then metabolized to form carb 
(Fig. 1).
DSF also produced an increase in NAc DA, decrease in GABA, and a biphasic effect on 
GLu first increasing and then decreasing GLu in the extracellular fluid (Fig. 6) similar to 
that observed in the NAc after carb administration (Fig. 2). DSF increased DA in the NAc, 
remained elevated for approximately 100 min and reached a maximal increase of 
approximately 111% (p< 0.05) over baseline. Although there was an initial increase in 
GABA in the extracellular fluid of the NAc within the first 10 min, GABA then decreased 
and remained at a reduced level for approximately two hours after DSF administration. GLu 
in the NAc exhibited a biphasic effect. GLu increased initially with a peak increase of 35% 
(p < 0.05) over baseline that occurred approximately 75 min after DSF dosing after which 
GLu decreased below basal levels. The maximal GLu decrease was 20% (p < 0.05) which 
occurred approximately 120 min after DSF administration. The peak concentration of DA, 
the maximal decrease in GABA, and the maximal increase and decrease in GLu (Fig. 6) 
after DSF was less than that observed after carb administration (Fig. 2) as would be 
expected. The changes in DA, GABA, and GLu in the NAc after an acute dose of DSF (Fig. 
6) was similar to that found after carb administration (Fig. 2) except that the concentration 
of these neurotransmitters after DSF dosing was lower. This is most likely due to less carb 
formed from DSF and the dose-dependent effect that carb has on these neurotransmitters 
(Fig. 2).
5.7. Inhibition of disulfiram metabolism with N-benzylimidazole and NAc dopamine, GABA, 
and glutamate
The hypothesis that the change in DA, GABA, and GLu in the NAc (Fig. 2) after DSF 
administration is due to formation of carb was tested using the general cytochrome P450 
inhibitor NBI to inhibit DSF metabolism. NBI (20 mg/kg i p) was given to rats 30 min 
before DSF administration and a booster dose of NBI given 30 min after DSF administration 
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in order to maintain inhibition of DSF metabolism (Hart and Faiman, 1993). The effect of 
the inhibition of DSF metabolism on DA, GABA, and GLu in the shell of the NAc is given 
in Fig. 7.
The concentration of DA, GABA, and GLu in the NAc between the NBI only (control 
group) and the NBI plus DSF group were not statistically different (p < 0.05) (Phase III). 
That is, NBI pretreatment blocked DSF-induced changes in these neurotransmitters. 
Although there was a minimal increase early in DA, GABA, and GLu in the NBI plus DSF 
treatment group, this increase was not statistically significant. In rats treated with DSF, carb 
was detected in both the NAc and plasma (Fig. 5). However, in rats treated with NBI and 
then given DSF, no carb could be detected in either the NAc or plasma. These findings 
suggest that in order for a DSF-induced change in DA, GABA, and GLu to occur, carb must 
first be formed. A summary of one-way ANOVA comparisons in NAc DA, GABA, and 
GLu during all three phases of the experimental protocol for the DSF plus NBI studies (Fig. 
7) is given in Table 3. During phase I, which is a measure of neurotransmitter base-line 
values 30 min before NBI treatment, no statistical differences were observed. Similarly, 
there were no statistical differences during phase II, which reflects the first 30 min after NBI 
treatment. Phase III, which is the region of maximal DA, GABA, and GLu response, 
statistically significant differences were apparent only with DA and GLu. Although the trend 
for GABA was in right direction, the small sample size may have contributed to the lack of 
any statistical significance in the GABA group.
5.8. Inhibition of carbamathione metabolism by N-benzylimidazole and NAc dopamine, 
GABA, and glutamate
NBI administration prior to carb dosing was investigated to determine if the inhibition of 
liver drug metabolizing enzymes had any effect on the carb-induced changes in DA, GABA, 
and GLu in the NAc once carb was formed (Fig. 8). In these studies carb was administered i 
p rather than given i v as in the dose–response studies (Fig. 2). Thus the effect of inhibition 
of the drug metabolism as well as comparing i p versus i v administration could be assessed. 
NBI had no effect on carb’s induced increase DA, decrease in GABA, and biphasic effect on 
GLu in the NAc, as the change observed in these neurotransmitters was similar to that 
observed after carb administration without NBI dosing (Fig. 2) An analysis of variance 
comparing DA, GABA, and GLu showed there was no statistical significance between the 
carb group (positive control) and NBI plus carb group. These findings suggest that once carb 
is formed, inhibition of liver cytochrome P450 enzymes has no effect on the basal levels of 
DA, GABA, and GLu. After i p carb administration, the values for the increase in DA, 
decrease in GABA and biphasic effect on GLu in the NAc are about half of that seen after i 
v carb administration (Fig. 2). This would be expected since absorption and distribution of 
carb to the brain must first occur after i p administration compared to a direct effect after i v 
administration. Since carb given i p produced changes in DA, GABA, and GLu in the NAc, 
these findings also suggest that first pass effects don’t play any role in carb’s ability to affect 
the vesicular release of these neurotransmitters.
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The finding that carb increased DA, decreased GABA, and had a biphasic effect on GLu in 
both the NAc and mPFC concurrently, is the first time this has been reported for a DSF 
metabolite. The mechanism by which carb produced these simultaneous changes in DA, 
GABA, and GLu in both the NAc and mPFC (Figs. 2 and 3) is unclear at this time. Since 
carb affects glutamate binding (Nagendra et al., 1997), the present studies were carried out 
to test the hypothesis that carb could affect DA, GABA, and GLu because of the interaction 
between these neurotransmitters, each of which can modulate their respective release 
(Sesack et al., 2003; Pierce and Kumaresan, 2006). Furthermore, the co-release of DA and 
GLu also has been suggested previously (Trudeau, 2004; Lapish et al., 2006). The increase 
in DA in the NAc and mPFC we observed after carb (Figs. 2 and 3) and DSF (Fig. 6) is 
similar to the findings from microdialysis studies by Vaccari et al. (1996) in which DSF and 
diethyldithiocarbamate (DDTC) (Fig. 1) increased the release of vesicular DA. Those 
investigators proposed that this was due to an interaction with the DA carrier and increased 
membrane permeability. However, from studies in progress (Levant and Faiman, 
unpublished results) we have observed that carb has no effect on the DA transporter. Vaccari 
et al. (1998), employing microdialysis techniques also found that DSF and DDTC increased 
the release of vesicular GLu from the neostriatum. Since DSF is metabolized to carb (Fig. 
1), it is more than likely that any changes in DA and GLu observed by those investigators 
most likely can be attributed to carb. Vaccari et al. (1998) did not observe a biphasic effect 
on GLu in contrast to our findings with carb given either i v (Figs. 2 and 3) or i p (Fig. 8), or 
DSF (Fig. 6).
The concentration of DA in the extracellular fluid of the NAc after carb administration (Fig. 
2) was greater than that found in the mPFC (Fig. 3). Furthermore, the time to reach the 
maximal increase in DA in the NAc after carb administration was approximately 15 min 
compared to approximately 50 min in the mPFC These findings are consistent with the 
findings from in vivo fast-scan cyclic voltammetry studies by Garris and Wightman (1994). 
Those studies showed that the initial rate of release of DA into the extracellular space was 
some 8-fold higher in the NAc than in the mPFC suggesting regional specific DA release 
characteristics. It is possible that the greater tonic DA concentration observed in the NAc 
compared to the mPFC arises from differences in phasic release. Although voltammetry and 
microdialysis data may not reflect the same phenomenon, our results parallel the findings of 
Garris and Wightman (1994). This also could explain the difference for the biphasic effect 
of GLu observed between results for carb (Figs. 2 and 3) and DSF (Fig. 6) and the DSF and 
DDTC findings of Vaccari et al. (1998).
The concentration of carb in the NAc and mPFC increased in a dose-dependent manner (Fig. 
4), and peaked within 5 min in both these brain regions regardless of the dose of carb 
administered, and was undetectable after 30 min. In plasma, carb peaked after 2.5 min and 
was undetectable after 12 min after a low dose and 26 min after a high dose of 
carbamathione (Fig. 4). However, the changes in DA, GABA and GLu in both the NAc and 
mPFC persisted for almost one to two hours (Figs. 2 and 3) long after carb could be detected 
in these brain regions (Fig. 4). This suggests that carb may either affect the vesicular storage 
and release of these neurotransmitters over a prolonged period of time and recovery is slow 
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while carb is rapidly removed, or that a metabolite of carb is responsible for the observed 
effect on these neurotransmitters. Studies in progress suggest the latter may be the case. The 
half-life for carb disappearance from the NAc, mPFC, or plasma are all similar, this being 
approximately 4 min regardless of the dose of carb administered (Table 2) suggesting first-
order kinetics and consistent with passive transfer. There was a direct relationship between 
the area under the curve (AUC) for carb and the dose of carb administered (Table 2) which 
again is consistent with first order kinetics.
DSF, the parent compound of carb, increased carb in the NAc and plasma (Fig. 5) and also 
increased NAc DA, decreased GABA, and had a biphasic effect on GLu (Fig. 6) similar to 
that observed after carb administration (Fig. 2). That the increase in DA after DSF is due to 
carb formation is supported by several lines of evidence. After DSF administration, carb 
appeared in both the NAc and plasma (Fig. 5A), and in addition there was an increase in 
NAc DA, decrease in GABA and a biphasic effect on GLu (Fig. 6) similar to that observed 
after carb administration (Fig. 2). The Cmax for carb in plasma and in the NAc after DSF 
administration (Fig. 5A) occurred after approximately 90 min whereas after carb 
administration (Fig. 5B), the Cmax in the NAc occurred within 5 min and in plasma within 
12 min. The differences between DSF and carb administration (Fig. 5A and B) is because 
DSF was given i p whereas carb, the active metabolite was given i v. The i p administration 
of DSF requires absorption, distribution and metabolism of the drug which explains the 
reason for the lag time before any changes in DA, GABA, and GLu occur (Fig. 6). The DSF 
inhibition studies with NBI provide further evidence that the increase in brain DA is due to 
carb and not the DSF metabolite DDTC as previously proposed (Goldstein et al., 1964). 
When DSF metabolism was inhibited by pretreatment with NBI, there was no statistical 
difference in DA, GABA, and GLu in the NAc between the NBI only-treated group 
(positive control) and the NBI plus DSF group (Fig. 7). Furthermore, no carb could be 
detected either in the NAc or in plasma in rats treated with NBI and then administered DSF. 
Thus, if no carb is formed, no changes in DA, GABA, and GLu were observed (Fig. 7). A 
comparison between i p DSF (Fig. 6) and i p carb (Fig. 8) further supports carb as the active 
metabolite responsible for the changes in DA, GABA, and GLu. The percentage of carb 
formed from DSF is unknown but is presumed to be small since Gessner and Jakubowski 
(1972) estimated that 0.05% of DDTC is converted to DDTC-Me, a precursor to carb (Fig.
1). Carb’s effect on NAc and mPFC DA, GABA, and GLu is dose-dependent (Figs. 2 and 
3). Thus, the change in concentration of these neurotransmitters formed after DSF 
administration (Fig. 6) is smaller when compared to carb (Fig. 8). Reduction of DSF to 
DDTC is dependent upon glutathione reductase ((Strömme, 1963a; Cobby et al., 1977) and 
not the cytochrome P450 enzymes. The CYP 3A4, 2E1 and 2A6 enzymes responsible for 
DSF bioactivation and carb formation (Madan et al., 1995) are necessary after formation of 
DDTC (Fig. 1). If DDTC is the metabolite responsible for the increase in DA after DSF 
administration as proposed (Goldstein et al., 1964), there should have been an increase in 
DA in the NAc after DSF administration in the NBI-treated rats since inhibition of the CYP 
enzymes by NBI occurs downstream from DDTC (Fig. 1). Therefore, once DDTC is 
formed, further metabolism to carb cannot proceed. In vivo, DDTC is rapidly methylated in 
both rodents (Gessner and Jakubowski, 1972), Cobby et al., 1977) and in humans ((Faiman 
et al., 1984), and demethylation of DDTC-Me to DDTC is unlikely (Gessner and 
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Jakubowski, 1972). Additional evidence that the formation of carb from DSF is required for 
any changes in these in these neurotransmitters is seen from the observation that the NAc/
plasma ratio after i v carb (Fig. 4) is approximately 0.16 which is similar to that for the NAc/
plasma ratio after DSF administration (Fig. 5A,), even though the route of administration 
was different, i v versus i p. Finally, that the CYP P450 enzymes are not involved in the 
metabolism of carb after it is formed from DSF is apparent from the findings that carb 
increased DA, decreased GABA, and had a biphasic effect on GLu in the NAc even when 
rats are first treated with NBI and then administered carb (Fig. 8). In addition, the 
pharmacokinetic parameters t1/2, Kelm, and AUC for carb with and without NBI 
pretreatment were similar providing further support that after carb is formed the CYP P450 
enzymes no longer play a role in carb’s effect on changes in DA, GABA, and GLu. An 
important finding is that carb, a glutathione conjugate, given i p crosses the blood brain 
barrier and affects DA, GABA, and GLu in the NAc (Fig. 8). Carb (200 mg/kg) was 
administered both i v and i p. Yet, the AUC, and t1/2 for both routes of administration were 
similar. Only the Cmax and tmax were different with the i p route taking longer to produce its 
effect which is expected.
From a clinical perspective, estimates suggest that adults reduce approximately 50 g of DSF 
within a 24 h period (Strömme, 1963b). This is a large dose of DSF compared to the 
standard 250 mg daily dose used clinically in treating alcohol or cocaine dependence. Thus, 
after the usual 250 mg clinical dose of DSF, little DSF should remain and any DDTC 
formed would be expected to be rapidly metabolized to several metabolites (Gessner and 
Jakubowski, 1972; Johansson, 1992; Madan et al., 1993, 1994) with little DDTC remaining. 
This is supported by human studies as less than 10 ng/ml of DDTC is found in plasma after 
a single dose of DSF (Scappaticci et al., 1990) and 0.7 µg/ml of DDTC found in plasma after 
12 consecutive days of dosing with DSF (Faiman et al., 1984).
These studies show for the first time that the DSF metabolite carb simultaneously increased 
DA, decreased GABA and increased and then decreased GLu in both the NAc and mPFC in 
a dose-dependent manner. Although it has been suggested that corelease of these 
neurotransmitters may occur in various disease states that implicate monoamine pathways 
(Trudeau, 2004), these findings are the first report that DSF as a result of carb formation can 
co-release these neurotransmitters. When the metabolism of DSF was inhibited, no carb was 
detected in brain and plasma, and no change in DA, GABA, and GLu occurred in the NAc.
An increase in brain DA and change in the DA/NE ratio due to DβH inhibition by DSF has 
been proposed as contributing to cocaine dependence ((Gaval-Cruz et al., 2008; Gaval-Cruz 
and Weinshenker, 2009; Schroeder et al., 2010). Although this concept may still be valid, 
the increase in DA appears to be due to carb and not DSF. We did not determine the effect 
of carb on DβH activity. However, carb is not a good drug candidate for inhibiting DβH 
(Hogarth, 2012) as is DDTC, which is the metabolite of DSF responsible for the inhibition 
of this enzyme (Goldstein et al., 1964). Furthermore, in very preliminary in vitro studies we 
found that carb does not bind to copper, the proposed mechanism by which DSF, through its 
metabolite DDTC complexes with the copper of DβH and inhibits this enzyme (Goldstein et 
al. (1964). As for DSF’s efficacy in cocaine dependence or non-substance abuse disorders 
such as pathological gambling, the co-release of DA, GABA, and GLu and their role cannot 
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be discounted considering carb’s simultaneous effect on these neurotransmitters. The 
neurocircuitry in the reward pathway in the brain associated with these neurotransmitters is 
such that each can influence the release of the other (McFarland and Kalivas, 2001; Del 
Arco and Mora, 2008). Focusing only on the role of either DA, GABA, or GLu individually 
in cocaine dependence, or other substance abuse disorders (Leshner and Koob, 1999), may 
only provide limited information. Of interest is that in studies by Yao et al. (2010), those 
investigators found that ALDH2 inhibition attenuates cocaine self-administration and 
prevents cocaine or cue-induced reinstatement in a rat model of cocaine relapse. The 
molecular mechanism proposed is that ALDH2 inhibition increases tetrahydropapaveroline 
(THP) formation through the condensation of 3,4-dihydroxyphenylacetaldehyde (DOPAL) 
and DA forming THP, which through a negative-feedback mechanism reduces DA 
production. Although this is an interesting concept, carb does not inhibit ALDH2 (Jin et al., 
1994; Nagendra et al., 1997), yet carb increases DA in the NAc and PFC (Figs. 2 and 3). 
Studies into carb’s mechanism of action in increasing DA are needed. Also, the present 
studies were carried out in naïve rats and the effect of carb in cocaine or any other substance 
abuse-dependent animal model both biochemically and behaviorally is unknown and needs 
to be determined.
7. Conclusions
DSF is a pro-drug and can be metabolized to a number of metabolites. The finding that the 
metabolite carb increased DA, decreased GABA, and had a biphasic effect on GLu in both 
the NAc and mPFC, and that these neurotransmitters are co-released represents a novel 
finding for this DSF metabolite. Inhibition of DSF metabolism prevented the formation of 
carb and attenuated the changes in DA, GABA, and GLu. Thus, carb must be formed in 
order for DSF to affect these neurotransmitters. The identification of carb as a modulator of 
DA, GABA, and GLu in the NAC and mPFC provides an opportunity for carb to be used as 
a pharmacological tool to better understand the mechanism of action of DSF, not only in 
cocaine dependence but other substance abuse disorders. In light of DSF’s effect on DA, 
GABA, and GLu in the NAc and mPFC, a central action for DSF in treating alcohol and 
cocaine dependence as well as non-substance-related dependencies cannot be excluded.
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Disulfiram bioactivation. DDTC: diethyldithiocarbamate. DDTC-Me: 
diethyldithiocarbamate methyl ester. DDTC-MeSO: diethyldithiocarbamate methyl ester 
sulfoxide. DETC-Me: S-methyl N, N-diethylthiolcarbamate. DETC-MeSO: S-methyl N, N-
diethylthiolcarbamate sulfoxide. DETC-MeSO2: S-methyl N, N-diethylthiolcarbamate 
sulfone. NBI: N-benzylimidazole.
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Dopamine, GABA, and glutamate concentration in the NAc after various doses of i v 
carbamathione. Perfusion of NAc was initiated 60 min before the i v administration of 
carbamathione (t = 0). Microdialysis samples were collected every 3 min for 
neurotransmitter analysis. The basal concentrations of dopamine, GABA, and glutamate in 
microdialysis samples from the NAc were 7.4 ± 1.8 nmol/L, 63.5 ± 11.7 nmol/L, and 2.9 ± 
0.5 µmol/L, respectively. Data shown as a percent of baseline (± SEM; n = 5). See Table 1 
for statistical analysis.
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Dopamine, GABA, and glutamate concentration in the mPFC after various doses of i v 
carbamathione. Perfusion of mPFC was initiated 60 min before the i v administration of 
carbamathione (t = 0). Microdialysis samples were collected every 3 min for 
neurotransmitter analysis. The basal concentrations of dopamine, GABA, and glutamate in 
microdialysis samples from the mPFC were 3.8 ± 0.5 nmol/L, 49.8 ± 11.7 nmol/L, and 2.4 ± 
0.3 µmol/L, respectively. Data shown as a percent of baseline (± SEM; n = 5). See Table 1 
for statistical analysis.
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Carbamathione concentration in the NAc, mPFC and plasma as a function of time after i v 
carbamathione administration. Data depict the mean carbamathione concentration (± SEM; n 
= 5) in the (A) NAc, mPFC and (B) plasma following carbamathione administration (20, 50, 
200 mg/kg i v). Microdialysis samples were collected every 3 min.
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Effect of disulfiram and carbamathione administration on NAc and plasma carbamathione. 
Data depict the mean carbamathione concentration (± SEM) in the NAc (circles) and plasma 
(squares) following (A) disulfiram (n = 3) or (B) carbamathione (n = 5) administration. 
Microdialysis samples were collected every 3 min for carbamathione and 5 min for 
disulfiram.
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Dopamine, GABA, and glutamate levels in the NAc following disulfiram (200 mg/kg; i p) 
administration. Perfusion of NAc was initiated 60 min before the i p administration of 
disulfiram (t = 0). Microdialysis samples were collected at 5 min intervals for 
neurotransmitter analysis. Data shown as mean percent of baseline (± SEM; n = 3).
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Dopamine, GABA, and glutamate in the NAc after inhibition of disulfiram metabolism. NBI 
(20 mg/kg; i p) was administered 30 min before disulfiram (200 mg/kg; i p) and a booster 
dose given 30 min after disulfiram (see arrows). Perfusion of NAc was initiated 60 min 
before the i v administration of disulfiram (t = 0). Arrows are the time at which NBI was 
administered. Microdialysis samples were collected at 5 min intervals for neurotransmitter 
analysis. Data shown as mean percent of baseline (± SEM; n = 3). Phase I represents a 
measure of the baseline 30 min before NBI treatment, Phase II reflects the first 30 min after 
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NBI administration, and Phase III is the region of maximal dopamine, GABA, and 
glutamate response. See Table 2 for statistical comparisons.
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Dopamine, GABA, and glutamate in the NAc after carbamathione administration with and 
without NBI. NBI (20 mg/kg; i p) was administered 30 min before carbamathione (200 
mg/kg; i p) and a booster dose of NBI given 30 min after carbamathione (see arrows). 
Perfusion of NAc was initiated 60 min before the i v administration of carbamathione (t = 
0). Microdialysis samples were collected at 5 min intervals for neurotransmitter analysis. 
Data shown as mean percent of baseline (± SEM; n = 3). A RM ANOVA indicated 
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carbamathione + NBI was significantly different from the NBI only group (p < 0.001) for 
DA, GABA, and Glu).
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Table 1
Summary of analysis of variance results for carbamathione dose–response studies. The table lists the ANOVA 
results for the main effect of dose. Statistical and post-hoc analysis were performed using a two-way repeated 
measures ANOVA.
Measurea Analysis of variance effectb
Dose
df F p
NAc DA 2,6 37.15 <0.01
NAc DA (200 mg vs 50 mg CARB) 1,4 91.79 <0.01
NAc DA (50 mg vs 20 mg CARB) 1,4 6.87 ns
NAc DA (200 mg vs 20 mg CARB) 1,4 58.56 <0.01
NAc GABA 2,6 148.36 <0.01
NAc GABA (200 mg vs 50 mg CARB) 1,4 104.64 <0.01
NAc GABA (50 mg vs 20 mg CARB) 1,4 77.46 <0.01
NAc GABA (200 mg vs 20 mg CARB) 1,4 209.58 <0.01
NAc GLu 2,6 27.54 <0.01
NAc GLu (200 mg vs 50 mg CARB) 1,4 23.54 <0.01
NAc GLu (50 mg vs 20 mg CARB) 1,4 5.15 ns
NAc GLu (200 mg vs 20 mg CARB) 1,4 37.44 <0.01
mPFC DA 2,6 265.08 <0.01
mPFC DA (200 mg vs 50 mg CARB) 1,4 501.92 <0.01
mPFC DA (50 mg vs 20 mg CARB) 1,4 53.03 <0.01
NAc DA (2000 mg vs 20 mg CARB) 1,4 394.46 <0.01
mPFC GABA 2,6 147.09 <0.01
mPFC GABA (200 mg vs 50 mg CARB) 1,4 133.17 <0.01
mPFC GABA (50 mg vs 20 mg CARB) 1,4 22.72 <0.01
NAc GABA (200 mg vs 20 mg CARB) 1,4 231.13 <0.01
mPFC GLu 2,6 37.69 <0.01
mPFC GLu (200 mg vs 50 mg CARB) 1,4 92.05 <0.01
mPFC GLu (50 mg vs 20 mg CARB) 1,4 1.69 ns
NAc GLu (200 mg vs 20 mg CARB) 1.4 57.23 <0.01
a
Post-hoc tests are in italics.
b
Significant probabilities are in bold font.
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